A director at Acomo NV maiden bought 11,500 shares at 17.560EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
We update our Acomo forecasts to account for the 10-month trading update and the latest moves in commodity prices. Due to the significant volume and margin declines in the Organic Ingredients segment, we reduce our 2023F adjusted EBITDA forecast by 12% and our 12-month target price by 15% to €21.63.
We update our Acomo forecasts to account for 2022 results and the latest moves in commodity prices, which have started to decline. Despite the price declines, we maintain our 12-month target price of €25.58 and our BUY rating as we expect Acomo to provide investors with a 25.6% total return over the next 12 months. Erratum for report dated 8 March in which 2022A results had not added back depreciation which affected EBITDA lines and below
We update our Acomo forecasts to account for 2022 results and the latest moves in commodity prices, which have started to decline. Despite the price declines, we maintain our 12-month target price of €25.58 and our BUY rating as we expect Acomo to provide investors with a 25.5% total return over the next 12 months.
Acomo: Busting a nut. DWS: Holding out for a Hero. Euronext: Calmer waters. Fugro: Refinancing and half year results. Heijmans: Preview; strong 1H but Dutch housing market cooling. Randstad: EBITA in line but underlying bit mixed; outlook 3Q22 seems below consensus. Sofina: Perturbing volatility necessitates purpose and patience. Unilever: Beats and raises
The independent financial analyst theScreener just lowered the general evaluation of AMSTERDAM COMMODITIES (NL), active in the Food Products industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date March 22, 2022, the clo...
AB InBev: Taking the rough with the smooth. Acomo: Fort-ifying the C-suite. AMG: 3Q21 miss but guidance maintained. FY2021 consensus remains feasible. Arcadis: Solid and with more to come. ArcelorMittal: 8% EBITDA beat, US$2.2bn more cash returned. Atenor: Sale of Hermes Business Campus. Cofinimmo: Strong results, stronger guidance. Fastned: Competitor Allego lists via SPAC. Fugro: Has growth definitively returned? Ontex: Turning the corner. Ordina: 2Q21 results, signi...
Accell: Pricing power. Acomo: Tradin well. Aedifica: New projects delivered. Basic-Fit: 1H21 review – strong membership ingrowth, club roll-out to accelerate in 2022. Econocom: Notable jump in profitability, on still weaker sales. Flow Traders: Bright spots in EMEA despite normalising volatility. KPN: 2Q21 preview. Signify: 2Q21 not as strong as expected. Sofina: Newsletter 8 characterized by high valuations.
Accell: Strong set of 1H20 results. Acomo: No fuss, no drama. Orange Belgium: 9% EBITDAal beat on lower costs, EBITDal guidance maintained. Proximus: 2Q20 preview. Royal Dutch Shell: A painful quarter and the largest write-down ever. Signify: Significant beat vs expectations in 2Q20. Telenet Group: 2Q20 preview
Summary Olam International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Olam International Ltd (Olam) engages in processing and distributing agricultural products and food ingredients. The company is involved in sourcing, primary processing, packaging and m...
The ING Benelux equity research team has performed a Covid-19 scenario analysis in order to provide a reference point for investors and to test if stocks: (a) have been relatively oversold in comparison to their earnings risk; (b) still provide downside risk; and/or have balance issues in a Covid-19 scenario; and (c) could bounce sharply if a vaccine is found; or (d) benefit relatively from the crisis. Our analysis results in lists of stocks that we consider: (1) low earnings risk, with attracti...
We update our Acomo forecasts to account for the latest moves in commodity prices, which have broadly stabilised. As a result, we raise our 12-month target price from €23.86 to €25.58 and maintain our BUY rating as we expect Acomo to provide investors with a 31% total return over the next 12 months.
The coronavirus continues to dominate the news headlines and in terms of number of infections has already exceeded the SARS number from 2003. What the impact will be on equity prices is uncertain and very much dependent on how rapidly the virus can be controlled and contained. Meantime, the measures being taken to control the spread are hitting world trade. Although the SARS outbreak saw only a temporary and limited impact, we feel with: (1) China now much more dominant in world trade; (2) faste...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.